

## JOANNE MOSS APPOINTED AS CHAIR ELECT OF THE BOARD

**Adelaide, Australia, 01 July 2021: LBT Innovations Limited (ASX: LBT) (LBT or the Company)** is delighted to announce the appointment of Ms Joanne Moss to its Board as independent Chair Elect. Ms Moss will commence as a Non-Executive Director, effective immediately, and transition into the role of Chair in September 2021. Current Chair, Ms Kate Costello, will support an orderly transition and then retire from the Board as planned.

### Key Points:

- **Joanne Moss to join LBT as Chair-Elect based on Board rejuvenation strategy**
- **Ms Moss to contribute board skillset in US commercialisation, deal strategy, scale up and capital raising**
- **Ms Moss is currently a non-executive director of Ellume, a rapidly growing digital diagnostic company in partnership with GSK, Qiagen and US Government**

Ms Moss has current board experience in the development, manufacture and commercialisation of medical devices and digital diagnostics and is ideally placed to lead LBT as it pursues international commercialisation of its world-leading technology and ongoing development of its pipeline of products.

LBT outgoing Chair, Kate Costello said:

*“We are thrilled to have Joanne join our Board and I am personally looking forward to working alongside her as she transitions to the role of Chair of the Company. Joanne has a deep understanding of the commercial pressures facing technology focused organisations and the challenges associated with scale-up and global commercialisation. She is seen as a thought leader and is regularly a keynote and panel speaker at industry roundtables and conferences. Joanne’s background in law and corporate governance, as well as her proven success as a non-executive director in the medtech industry will add considerably to the existing skills and experience of the Board.”*

Incoming Chair Elect, Joanne Moss said:

*“LBT is an example of Australian innovation at its finest and I am delighted to join the team. LBT is in the early stages of global commercialisation of its ground-breaking technology and I very much look forward to sharing my knowledge and experience to help fast track LBT’s future growth and success.”*

Ms Moss is an independent Non-Executive Director, Chair of Audit and Risk Committee, and Member of the Nominations and Remuneration Committee of award-winning Australian company, Ellume Limited. Ellume develops, manufactures and commercialises digital diagnostic products for consumers, healthcare professionals and laboratories. Ms Moss has contributed significantly to Ellume’s deal strategy, US commercialisation efforts, scale up and capital-raising. Earlier this year, Ellume secured a \$302m contract with the US Government shortly after the FDA authorised Ellume’s first-of-its-kind Covid-19 home test. Ellume recently announced a partnership with AZOVA to make its Covid-19 home tests available to Delta Air Lines customers.

Ms Moss is an experienced senior executive with a background in legal advisory, risk, corporate governance, compliance and stakeholder engagement. Commencing her career at global law firm Norton Rose Fulbright, Ms Moss was an adviser to public and private companies across the corporate/M&A, banking and finance, infrastructure and commercial litigation practice groups. More recently, Ms Moss held the position of Chief Legal and Corporate Affairs Officer at Pizza Hut Australia, a brand within Fortune 500 company Yum!. In this board facing role, Ms Moss contributed to the company’s commercial and digital transformation.

Ms Moss is admitted to the High Court of Australia and to the Supreme Courts of NSW and WA. She holds a Bachelor of Laws (Hons 1<sup>st</sup>), a Master of Laws in International Law (Distinction), a Certificate of Chinese Laws and Legal Systems, a Mini MBA through Global Leaders in Law at Oxford, and has undertaken further studies at the Governance Institute of Australia and National Association of Company Directors in the US.

## Remuneration and Relevant Interests

From the commencement of her role with LBT, Ms Moss will be paid directors fees consistent with existing non-executive directors and will receive a one-off grant of 1.25 million options, subject to shareholder approval, vesting over two years and with a strike price of \$0.081. In accordance with the Board policy announced on 26 March 2021, Ms Moss has also committed to direct 25% of her future LBT director fees to acquire new LBT shares, again subject to shareholder approval.

An Appendix 3X for Ms Moss is attached with this announcement.

Approved for release by the LBT Board.

– ENDS –

## About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak<sup>®</sup>, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS<sup>®</sup>) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. Beckman Coulter have also been appointed as Marketing Agent in Europe to assist in facilitating sales. The APAS<sup>®</sup> instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

## CONTACTS

LBT Innovations	Investor Enquiries
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>	<b>David Allen / John Granger</b> Hawkesbury Partners Tel: +61 2 9103 9494 E: <a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a>

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>LBT INNOVATIONS LTD</b>
<b>ABN</b>	<b>95 107 670 673</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Ms Joanne Moss</b>
<b>Date of appointment</b>	<b>1 July 2021</b>

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
<b>Nil</b>

+ See chapter 19 for defined terms.

## Appendix 3X Initial Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of Securities</b>
Note: Provide details of the circumstances giving rise to the relevant interest.	
N/A	

### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	N/A

---

+ See chapter 19 for defined terms.